CN
GV20 ONCOTHERAPY
GV20 Oncotherapy was started by expert team from Harvard University. We are devoted in cancer immuno-oncology precision medicine development. GV20 Oncotherapy has created new generation of cancer novel drug discovery and development platform which integrates cancer genomics, antibody drug design and biological big data mining. We are utilizing our technological advantages to search novel immuno-oncology targets, screen tumor-specific fully human antibody and identify robust response biomarkers.
Technology platforms
Novel Immuno-Oncology Targets
Tumor-Specific Fully Human Antibodies
Robust Response Biomarkers
Atlas Genomics PlatformTumor profile,CRISPR screen,
Antibody screen
Phial AI PlatformBig data & Machine learning algorithms
investors
  • Linear Capital

  • IDG

  • WATSON

China
Address:Room 801, 781 Cailun Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China
Email:bd@bioxbh.com
USA
Address:One Broadway, 14th floor, Kendall Square, Cambridge, MA 02142, USA
Email:hr@gv20therapeutics.com